Medicare Coverage for Atrial Fibrillation (AFib): 2025 Guide
Atrial fibrillation is the most common heart rhythm disorder, affecting an estimated 6–7 million Americans — and the prevalence rises steeply with age. AFib increases stroke risk by 5x and is responsible for 1 in 4 strokes in older adults. Medicare covers the full spectrum of AFib care: diagnosis, rhythm and rate control, anticoagulation, catheter ablation, and the Watchman device for patients who cannot take blood thinners long-term.
AFib Coverage Quick Reference
| Service | Part | Your Cost (2025) | Notes |
|---|---|---|---|
| EKG / electrocardiogram | Part B | 20% after $257 deductible | Primary diagnostic tool for AFib |
| Holter monitor (24–48 hour) | Part B (DME) | 20% after deductible | Continuous rhythm monitoring for paroxysmal AFib detection |
| Extended cardiac monitor (30-day) | Part B (DME) | 20% after deductible | For intermittent AFib; patch-style or event monitors |
| Implantable loop recorder (ILR) | Part B | 20% after deductible | Subcutaneous implant for long-term arrhythmia monitoring |
| Echocardiogram (TEE/TTE) | Part B | 20% after deductible | Cardiac structure evaluation; TEE before cardioversion |
| Cardiologist / electrophysiologist visits | Part B | 20% after deductible | Ongoing AFib management |
| Electrical cardioversion (DCCV) | Part B or Part A | 20% (outpatient) or A deductible | Outpatient shock to restore normal rhythm |
| Catheter ablation | Part A (inpatient) or Part B | $1,676 deductible or 20% | Radiofrequency or cryo; most performed inpatient |
| Watchman device (LAAO) | Part A | $1,676 deductible per benefit period | Left atrial appendage occlusion; for anticoagulant-ineligible patients |
| Pacemaker implantation | Part A | $1,676 deductible | For AFib with bradycardia or post-ablation AV block |
| Apixaban (Eliquis) | Part D | Up to $2,000 OOP cap/year | Most prescribed NOAC for AFib stroke prevention |
| Rivaroxaban (Xarelto) | Part D | Up to $2,000 OOP cap/year | Once-daily dosing NOAC |
| Warfarin (Coumadin) | Part D | Tier 1 generic; <$10/month | Requires regular INR monitoring; very inexpensive |
| Rate control medications (metoprolol, diltiazem) | Part D | Tier 1 generic; very low cost | Beta blockers and calcium channel blockers for rate control |
| Antiarrhythmics (flecainide, amiodarone) | Part D | Tier 1–2; generics available | Rhythm control medications |
| INR monitoring (for warfarin) | Part B | 20% after deductible | Regular lab checks required for warfarin dosing |
| Remote cardiac monitoring (RPM) | Part B | 20% after deductible | Connected cardiac monitors with physician data review |
Diagnosing AFib: Cardiac Monitoring Coverage
AFib — especially paroxysmal (intermittent) AFib — can be difficult to catch on a standard EKG. Medicare covers progressively longer monitoring options:
- Resting EKG: 12-lead EKG; covered at 20% coinsurance. Catches AFib only if you're in it during the test
- Holter monitor (24–48 hours): Continuous recording worn home; good for frequent symptoms
- Extended event monitor (up to 30 days): Patch-style monitor worn longer; better for infrequent episodes
- Implantable loop recorder (ILR): Tiny device placed under the skin; monitors for up to 3 years. Covered under Part B for appropriate diagnostic indications, including cryptogenic stroke workup
Anticoagulation: The Critical Stroke Prevention Treatment
Anticoagulation (blood thinners) is the most important intervention to prevent AFib-related stroke. Medicare covers all current anticoagulant options under Part D:
NOACs (Novel/Direct Oral Anticoagulants)
Eliquis (apixaban), Xarelto (rivaroxaban), Pradaxa (dabigatran), and Savaysa (edoxaban) are the preferred anticoagulants for most AFib patients. They do not require regular blood monitoring and have predictable dosing.
Cost under 2025 Medicare:
- List price: approximately $5,000–$7,000/year
- Your Part D cost: up to $2,000 maximum OOP per year (2025 cap)
- Earlier in the year you spend the $2,000, the rest of the year your drug costs drop to $0
- Generic apixaban expected in 2028; generic rivaroxaban available in some markets
Warfarin
Warfarin remains an option, particularly for patients with mechanical heart valves (for whom NOACs are contraindicated):
- Generic cost: typically $3–$10/month under Part D
- Requires regular INR blood testing (covered under Part B)
- More drug and food interactions than NOACs
- Home INR monitoring devices: covered under Part B DME for eligible patients
Catheter Ablation: Medicare Coverage
Catheter ablation is a procedure that destroys or isolates the abnormal electrical pathways causing AFib. It's performed by an electrophysiologist and is increasingly used as first-line or second-line therapy for symptomatic AFib.
Types and coverage:
- Radiofrequency (RF) ablation: Covered under Medicare; typically performed inpatient (Part A)
- Cryoablation (Arctic Front): Covered; freezes pulmonary vein tissue to create isolation
- Pulsed Field Ablation (PFA): Newer technology (Farapulse received FDA approval 2023); Medicare coverage determined on a case-by-case basis as national coverage decision develops
Ablation is most effective for paroxysmal AFib (intermittent episodes) in patients without severely enlarged atria. It does not eliminate the need for ongoing anticoagulation in high-stroke-risk patients.
The Watchman Device: An Alternative to Lifelong Blood Thinners
The Watchman (and newer Watchman FLX) is a small device implanted in the left atrial appendage — the area of the heart where most AFib-related clots form. It provides stroke protection without requiring lifelong anticoagulation.
Medicare covers the Watchman when:
- You have non-valvular AFib
- You have a clinical reason why long-term anticoagulation is not appropriate (bleeding history, fall risk, patient preference)
- You are suitable for short-term anticoagulation therapy post-implant (typically 45 days)
- The procedure is performed at a Medicare-approved facility by a qualified operator
Coverage is under Part A (inpatient procedure). The Part A deductible of $1,676 applies. After device placement, anticoagulation is typically continued for 45 days, then replaced with aspirin + clopidogrel, and eventually aspirin alone after a follow-up imaging study confirms closure.
Rate Control vs. Rhythm Control: Medication Coverage
AFib management involves two strategies: controlling how fast the heart beats (rate control) or restoring normal rhythm (rhythm control). Medicare covers both approaches:
Rate Control
- Beta blockers (metoprolol, atenolol, carvedilol) — generic, Tier 1, very low cost
- Calcium channel blockers (diltiazem, verapamil) — generic, Tier 1, very low cost
- Digoxin — generic, very inexpensive
Rhythm Control
- Flecainide — generic available, Tier 1–2
- Propafenone — generic available
- Amiodarone — generic available, very inexpensive; requires thyroid/liver monitoring
- Sotalol — generic available
- Dronedarone (Multaq) — brand only; Tier 3–4; check formulary
Frequently Asked Questions
Yes. Eliquis (apixaban) is covered under Medicare Part D for AFib stroke prevention. At its list price of approximately $6,000/year, it falls into the catastrophic coverage phase — but starting in 2025, your total Part D out-of-pocket spending is capped at $2,000 per year. This means your maximum annual cost for Eliquis is $2,000 regardless of list price. If you've been avoiding Eliquis due to cost, 2025's cap changes the math significantly.
Yes. Medicare covers catheter ablation for atrial fibrillation, typically as an inpatient procedure under Part A. You pay the Part A deductible ($1,676 per benefit period). Most ablations are performed when antiarrhythmic medications have failed or when ablation is preferred as initial rhythm control therapy. Medigap Plan G covers the Part A deductible and coinsurance. Ask your electrophysiologist whether your AFib type and anatomy make you a good ablation candidate.
Yes, when criteria are met. The Watchman left atrial appendage closure device is covered under Medicare Part A for patients with non-valvular AFib who have a reason why long-term anticoagulation is not appropriate — such as a history of significant bleeding, high fall risk, or inability to tolerate blood thinners. The Part A deductible ($1,676) applies. The procedure must be performed by a credentialed operator at a qualified facility. A multidisciplinary team evaluation (cardiologist + cardiac surgeon) is typically required.